Trial Profile
Phase II Study of Azacytidine Followed by GM-CSF in Patients With Low- or Intermediate-1- Risk Myelodysplastic Syndrome (MDS).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Granulocyte macrophage colony stimulating factor; Granulocyte macrophage colony stimulating factor
- Indications Myelodysplastic syndromes
- Focus Pharmacogenomic; Therapeutic Use
- 01 Apr 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Mar 2012 New source identified and integrated (M.D. Anderson Cancer Center record).